AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03443544 — intervention group
Intervention type: PROCEDURE
Intervention: Aggressive debridement
Description: Aggressive debridement of the tissues undergoing fascitis
Study NCT00326040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma Surgery
Study NCT00505362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus closure
Description: Reapproximation of the rectus muscles with three-interrupted sutures
Study NCT01243125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422, 0.2%
Description: 0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Study NCT01243125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline, 0.9%
Description: Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Study NCT03281538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
Study NCT04286503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrimycin
Description: Carrimycin
Study NCT04286503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
Description: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
Study NCT04286503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic treatment
Description: basic treatment
Study NCT04286503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basic treatment
Description: basic treatment
Study NCT06391515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample, CRF, thyroid ultrasound
Description: Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.
Study NCT01050842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally
Study NCT01050842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: Given orally
Study NCT01050842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study
Study NCT00593645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Study NCT00593645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT00593645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study NCT00593645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Study NCT02207179 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: LumaScan Image Guided Surgery
Study NCT04000711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient oral treatment.
Description: Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC > 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
Study NCT04000711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient intravenous treatment.
Description: Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC > 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
Study NCT03519607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FertiStrong App
Description: The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
Study NCT03049800 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
Study NCT00583804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IST-12
Description: Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
Study NCT00583804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IST-12
Description: Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
Study NCT04102111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67864238
Description: Participants will receive oral tablets of JNJ-67864238 twice daily.
Study NCT04102111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral tablets of matching placebo twice daily.
Study NCT03509597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Physical exercise training consisting of aerobic exercise and strength/resistance training.
Study NCT03509597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Cognitive remediation program using REHACOP rehabilitation program.
Study NCT03509597 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as usual
Description: Standard care for schizophrenia + Leisure and free time activities.
Study NCT03509597 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Occupational Activities
Description: Engagement in activities aimed to keep patients actively involved in demanding tasks.
Study NCT03132259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose dexmedethomidine
Description: Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
Study NCT03132259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose dexmedethomidine
Description: Dexmedethomidine continuous drip 0.2 mcg/kg/hr
Study NCT01300520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Target Tape
Description: Comparing procedures using Target Tape against procedures not using Target Tape
Study NCT01451788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin matrix with human derived thrombin (Floseal, Baxter)
Description: Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
Study NCT02070991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: oral tablet, 10 mg once daily
Study NCT02070991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT04151498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reengagement and Assessment Mobile Program
Description: Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
Study NCT04151498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative Interview
Description: Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
Study NCT04151498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview
Description: Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
Study NCT02473601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivacurium Chloride
Description: Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane.
Study NCT02473601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mivacurium Chloride
Description: Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane.
Study NCT02212977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate
Description: Skin incision closure with topic skin adhesive Octylcyanoacrylate
Study NCT02212977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
Study NCT06447896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000)
Description: Cardiovascular autonomic reflex tests (CARTs) and heart rate variability analysis (HRV) are conducted with Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000). CARTs include five standardized tests, which are heart rate response to lying-to-standing, Valsalva maneuver, deep breathing, and blood pressure response to lying-to-standing and sustained isometric handgrip. These series of movements act as standardized stimuli to trigger hemodynamic changes in the body, altering vagal and sympathetic activity through mechanisms such as the baroreflex, thereby producing changes in heart rate and blood pressure. The sensor-monitoring interactive design of the device ensures the standardization of these maneuvers.
Study NCT06447896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method of CARTs
Description: Conventional method are conduced using blood pressure kit with manual sphygmomanometer and ECG machine. Conventional method and the investigated device are used simultaneously to record electrocardiograms. Conventional blood pressure taking are carried out in sequence with the investigated device. CARTs results from the conventional method are used as control.
Study NCT06447896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory holter station Model i12 plus
Description: Model i12 plus (manufactured by RENCARE) is an ambulatory holter station, which was approved by the Center for Medical Device Evaluation (CMDE), China National Medical Products Association (NMPA). It can analyze electrocardiogram and generate HRV indices, which include SDNN, RMSSD, NN50, pNN50, triangular index, average RR, deceleration capacity (DC), deceleration runs (DRs), VLF, LF, HF, LF/HF, and total power. Model i12 plus is used to analyzed the same ECG signals as the investigated device.
Study NCT01119222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Capsule, single 1200mg dose
Study NCT01119222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Tablet, single 50mg dose
Study NCT01119222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: IV, single 10mg dose
Study NCT01119222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
Study NCT04077606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ceramo-metallic crown prepartion
Description: tooth will be prepared to receive ceramo-metallic crowns
Study NCT04077606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full anatomical monolithic zirconia crown
Description: tooth will be prepared to receive monolithic zirconia crowns
Study NCT04063020 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological monitoring
Description: Discussions with the psychologist PhD student before and after every surgery times : 3 discussions.~* Before the first surgery (about 1 month before) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)~* Before the second surgery (3 months later the first surgery) Clinical interview Drawing a person~* After the second surgery (15 months later the first surgery) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coartem
Description: Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
Study NCT01507389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.75 mg injected subcutaneously (under the skin)
Study NCT05045599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health
Description: Community engagement to improve awareness, and use of family planning products and services
Study NCT05045599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health
Description: Community engagement to improve awareness, and use of family planning products and services
Study NCT04220281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol infusion during surgery
Study NCT04220281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: nitroglycerin infusion during surgery
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coartem
Description: Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
Study NCT03952650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibuprofen
Description: Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
Study NCT03904186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QUIT
Description: QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
Study NCT03904186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-Matched Control (TM)
Description: Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
Study NCT01436292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% human albumin solution (HAS)
Description: Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS.
Study NCT02828085 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasal swab
Description: Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
Study NCT00288340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: functional magnetic resonance imaging
Study NCT00058370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00058370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study NCT00058370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00058370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00058370 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody 3F8
Study NCT00058370 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02203682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Description: Tab. Doxycycline 50 mg PO per day for 12 weeks
Study NCT02203682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet placebo for 12 weeks
Study NCT02127268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin-α1
Description: with Thymosin-α1 1.6mg twice a week
Study NCT00972647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser beam guidance
Description: Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
Study NCT01142089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
Study NCT04282928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell
Study NCT04282928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: According toInfluenza diagnosis and treatment plan (2019 version)
Study NCT04282928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: According toInfluenza diagnosis and treatment plan (2019 version)
Study NCT00441740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
Study NCT00441740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
Study NCT00441740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles